172 related articles for article (PubMed ID: 19755674)
1. The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patients.
Paiva B; Vidriales MB; Mateo G; Pérez JJ; Montalbán MA; Sureda A; Montejano L; Gutiérrez NC; García de Coca A; de las Heras N; Mateos MV; López-Berges MC; García-Boyero R; Galende J; Hernández J; Palomera L; Carrera D; Martínez R; de la Rubia J; Martín A; González Y; Bladé J; Lahuerta JJ; Orfao A; San-Miguel JF;
Blood; 2009 Nov; 114(20):4369-72. PubMed ID: 19755674
[TBL] [Abstract][Full Text] [Related]
2. Impact of bone marrow plasma cells percentage on survival at diagnosis and pre-transplant period in newly diagnosed multiple myeloma: Experience of a single center from Turkey.
Ciftciler R; Goker H; Buyukasık Y; Aladag E; Saglam EA; Demiroglu H
Transfus Apher Sci; 2019 Jun; 58(3):313-317. PubMed ID: 30928228
[TBL] [Abstract][Full Text] [Related]
3. The prognostic value of multiparametric flow cytometry in AL amyloidosis at diagnosis and at the end of first-line treatment.
Muchtar E; Jevremovic D; Dispenzieri A; Dingli D; Buadi FK; Lacy MQ; Gonsalves W; Hayman SR; Kapoor P; Leung N; Russell S; Lust JA; Lin Y; Go RS; Chakraborty R; Zeldenrust S; Kumar SK; Kyle RA; Rajkumar SV; Gertz MA
Blood; 2017 Jan; 129(1):82-87. PubMed ID: 27729322
[TBL] [Abstract][Full Text] [Related]
4. Multiparameter flow cytometry quantification of bone marrow plasma cells at diagnosis provides more prognostic information than morphological assessment in myeloma patients.
Paiva B; Vidriales MB; Pérez JJ; Mateo G; Montalbán MA; Mateos MV; Bladé J; Lahuerta JJ; Orfao A; San Miguel JF; ;
Haematologica; 2009 Nov; 94(11):1599-602. PubMed ID: 19880781
[TBL] [Abstract][Full Text] [Related]
5. A new staging system for multiple myeloma based on the number of S-phase plasma cells.
San Miguel JF; García-Sanz R; González M; Moro MJ; Hernández JM; Ortega F; Borrego D; Carnero M; Casanova F; Jiménez R
Blood; 1995 Jan; 85(2):448-55. PubMed ID: 7811998
[TBL] [Abstract][Full Text] [Related]
6. BrdU incorporation in multiparameter flow cytometry: A new cell cycle assessment approach in multiple myeloma.
Requirand G; Robert N; Boireau S; Vincent L; Seckinger A; Bouhya S; Ceballos P; Cartron G; Hose D; Klein B; Moreaux J
Cytometry B Clin Cytom; 2019 May; 96(3):209-214. PubMed ID: 30417559
[TBL] [Abstract][Full Text] [Related]
7. Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: a tool for comparing the efficacy of different treatment strategies and predicting outcome.
San Miguel JF; Almeida J; Mateo G; Bladé J; López-Berges C; Caballero D; Hernández J; Moro MJ; Fernández-Calvo J; Díaz-Mediavilla J; Palomera L; Orfao A
Blood; 2002 Mar; 99(5):1853-6. PubMed ID: 11861305
[TBL] [Abstract][Full Text] [Related]
8. Clinical applicability and prognostic significance of molecular response assessed by fluorescent-PCR of immunoglobulin genes in multiple myeloma. Results from a GEM/PETHEMA study.
Martinez-Lopez J; Fernández-Redondo E; García-Sánz R; Montalbán MA; Martínez-Sánchez P; Pavia B; Mateos MV; Rosiñol L; Martín M; Ayala R; Martínez R; Blanchard MJ; Alegre A; Besalduch J; Bargay J; Hernandez MT; Sarasquete ME; Sanchez-Godoy P; Fernández M; Blade J; San Miguel JF; Lahuerta JJ;
Br J Haematol; 2013 Dec; 163(5):581-9. PubMed ID: 24117042
[TBL] [Abstract][Full Text] [Related]
9. Immunophenotypic characterization and quantification of neoplastic bone marrow plasma cells by multiparametric flow cytometry and its clinical significance in Korean myeloma patients.
Cho YU; Park CJ; Park SJ; Chi HS; Jang S; Park SH; Seo EJ; Yoon DH; Lee JH; Suh C
J Korean Med Sci; 2013 Apr; 28(4):542-9. PubMed ID: 23580331
[TBL] [Abstract][Full Text] [Related]
10. Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma.
Flores-Montero J; de Tute R; Paiva B; Perez JJ; Böttcher S; Wind H; Sanoja L; Puig N; Lecrevisse Q; Vidriales MB; van Dongen JJ; Orfao A
Cytometry B Clin Cytom; 2016 Jan; 90(1):61-72. PubMed ID: 26100534
[TBL] [Abstract][Full Text] [Related]
11. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma.
Rajkumar S; Fonseca R; Lacy M; Witzig T; Lust J; Greipp P; Therneau T; Kyle R; Litzow M; Gertz M
Bone Marrow Transplant; 1999 Sep; 24(5):497-503. PubMed ID: 10482933
[TBL] [Abstract][Full Text] [Related]
12. Differentiation stage of myeloma plasma cells: biological and clinical significance.
Paiva B; Puig N; Cedena MT; de Jong BG; Ruiz Y; Rapado I; Martinez-Lopez J; Cordon L; Alignani D; Delgado JA; van Zelm MC; Van Dongen JJ; Pascual M; Agirre X; Prosper F; Martín-Subero JI; Vidriales MB; Gutierrez NC; Hernandez MT; Oriol A; Echeveste MA; Gonzalez Y; Johnson SK; Epstein J; Barlogie B; Morgan GJ; Orfao A; Blade J; Mateos MV; Lahuerta JJ; San-Miguel JF
Leukemia; 2017 Feb; 31(2):382-392. PubMed ID: 27479184
[TBL] [Abstract][Full Text] [Related]
13. Circulating plasma cells in newly diagnosed symptomatic multiple myeloma as a possible prognostic marker for patients with standard-risk cytogenetics.
Vagnoni D; Travaglini F; Pezzoni V; Ruggieri M; Bigazzi C; Dalsass A; Mestichelli F; Troiani E; Falcioni S; Mazzotta S; Natale A; Angelini M; Ferretti S; Angelini S; Galieni P
Br J Haematol; 2015 Aug; 170(4):523-31. PubMed ID: 26010293
[TBL] [Abstract][Full Text] [Related]
14. Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation.
Rawstron AC; Davies FE; DasGupta R; Ashcroft AJ; Patmore R; Drayson MT; Owen RG; Jack AS; Child JA; Morgan GJ
Blood; 2002 Nov; 100(9):3095-100. PubMed ID: 12384404
[TBL] [Abstract][Full Text] [Related]
15. A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control.
Paiva B; Vídriales MB; Rosiñol L; Martínez-López J; Mateos MV; Ocio EM; Montalbán MÁ; Cordón L; Gutiérrez NC; Corchete L; Oriol A; Terol MJ; Echeveste MA; De Paz R; De Arriba F; Palomera L; de la Rubia J; Díaz-Mediavilla J; Granell M; Gorosquieta A; Alegre A; Orfao A; Lahuerta JJ; Bladé J; San Miguel JF;
Leukemia; 2013 Oct; 27(10):2056-61. PubMed ID: 23743858
[TBL] [Abstract][Full Text] [Related]
16. Multiparameter flow cytometry evaluation of plasma cell DNA content and proliferation in 595 transplant-eligible patients with myeloma included in the Spanish GEM2000 and GEM2005<65y trials.
Paiva B; Vídriales MB; Montalbán MÁ; Pérez JJ; Gutiérrez NC; Rosiñol L; Martínez-López J; Mateos MV; Cordón L; Oriol A; Terol MJ; Echeveste MA; De Paz R; De Arriba F; Palomera L; de la Rubia J; Díaz-Mediavilla J; Sureda A; Gorosquieta A; Alegre A; Martin A; Lahuerta JJ; Bladé J; Orfao A; San Miguel JF
Am J Pathol; 2012 Nov; 181(5):1870-8. PubMed ID: 22974582
[TBL] [Abstract][Full Text] [Related]
17. Multiple myeloma in serologic complete remission after autologous stem cell transplantation: impact of bone marrow plasma cell assessment by conventional morphology on disease progression.
Fernández de Larrea C; Tovar N; Rozman M; Rosiñol L; Aróstegui JI; Cibeira MT; Rovira M; Yagüe J; Bladé J
Biol Blood Marrow Transplant; 2011 Jul; 17(7):1084-7. PubMed ID: 21215814
[TBL] [Abstract][Full Text] [Related]
18. Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in AL amyloidosis.
Muchtar E; Gertz MA; Kourelis TV; Sidana S; Go RS; Lacy MQ; Buadi FK; Dingli D; Hayman SR; Kapoor P; Leung N; Fonder A; Hobbs M; Lisa Hwa Y; Gonsalves W; Warsame R; Russell S; Lust JA; Lin Y; Zeldenrust S; Rajkumar SV; Kyle RA; Kumar SK; Dispenzieri A
Leukemia; 2020 Apr; 34(4):1135-1143. PubMed ID: 31758090
[TBL] [Abstract][Full Text] [Related]
19. Bone marrow plasma cell assessment before peripheral blood stem cell mobilization in patients with multiple myeloma undergoing autologous stem cell transplantation.
Lee SE; Yoon JH; Shin SH; Eom KS; Kim YJ; Kim HJ; Lee S; Cho SG; Lee JW; Min WS; Park CW; Kim M; Min CK
Biomed Res Int; 2014; 2014():982504. PubMed ID: 24895639
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients.
Paiva B; Gutiérrez NC; Chen X; Vídriales MB; Montalbán MÁ; Rosiñol L; Oriol A; Martínez-López J; Mateos MV; López-Corral L; Díaz-Rodríguez E; Pérez JJ; Fernández-Redondo E; de Arriba F; Palomera L; Bengoechea E; Terol MJ; de Paz R; Martin A; Hernández J; Orfao A; Lahuerta JJ; Bladé J; Pandiella A; Miguel JF;
Leukemia; 2012 Aug; 26(8):1862-9. PubMed ID: 22333880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
